
MetasTx: Innovating prostate cancer treatments since 2021, focusing on metastasis prevention.
Founded in 2021, MetasTx is dedicated to innovating treatments for prostate cancer, specifically focusing on preventing and treating metastasis without impacting the Androgen System. The company's core mission is to develop novel therapeutics that address the critical challenge of cancer spread, aiming to transform the future of cancer treatment. MetasTx's market focus is on providing advanced medical solutions for prostate cancer patients, leveraging cutting-edge scientific research to achieve their vision.
MetasTx has attracted notable investors and experts in the oncology field, contributing to its rapid progress and credibility. The company has achieved significant milestones in its research pipeline, showcasing promising results in preclinical trials. By addressing the unmet needs in prostate cancer treatment, MetasTx is making a substantial impact on the medical community and improving patient outcomes.

MedicaMetrix
medicametrix.com

Novasenta
novasenta.com

Metaclipse Therapeutics

ImmunoMet Therapeutics
immunomet.com

Palm Therapeutics

EtiraRx
etirarx.com

Oncternal Therapeutics
oncternal.com

LifeBridge Innovations

Metfora
metfora.com

Window Therapeutics
windowtx.com

Novita Pharmaceuticals
novita-pharm.com

OncoSpherix
oncospherix.com

Sporos Bioventures

OncoPrecision
oncoprecision.bio

Faeth Therapeutics
Companies similar to MetasTx include MedicaMetrix, Novasenta, Metaclipse Therapeutics and ImmunoMet Therapeutics.
MetasTx was founded in 2021.
MetasTx's headquarters is located in Basking Ridge, NJ, US.
MetasTx's most recent funding round was for $100k (USD) in December 2023.
As of Dec 6, 2023, MetasTx has raised a total of $100k (USD).
MetasTx has 3 employees as of Feb 4, 2024.